Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on December 23, 2004

Arteriosclerosis, Thrombosis, and Vascular Biology. 2004
Published online before print December 23, 2004, doi: 10.1161/01.ATV.0000154140.73570.00
A more recent version of this article appeared on March 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
25/3/585    most recent
01.ATV.0000154140.73570.00v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duez, H.
Right arrow Articles by Staels, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duez, H.
Right arrow Articles by Staels, B.

Submitted on July 15, 2004
Accepted on November 19, 2004

Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor {alpha} Modulation

Hélène Duez *; Bruno Lefebvre ; Philippe Poulain ; Inés Pineda Torra ; Frédéric Percevault ; Gérald Luc ; Jeffrey M. Peters ; Frank J. Gonzalez ; Romain Gineste ; Stéphane Helleboid ; Jean-Charles Fruchart ; Catherine Fiévet ; Philippe Lefebvre ; and Bart Staels

From UR.545INSERM, Département d’Athérosclérose (H.D., P.P., I.P.T., F.P., G.L., J.-C.F., C.F., B.S.), Institut Pasteur Lille and Faculté de Pharmacie, Université de Lille2, France; UR.459INSERM, Biologie Moléculaire des Récepteurs Nucléaires (B.L., P.L.), Faculté de Médecine Lille, France; the Department of Veterinary Science (J.M.P.), Center for Molecular Toxicology, Pennsylvania State University, Hershey, Penn; the Laboratory of Metabolism (F.J.G.), National Cancer Institute, National Institute of Health, Bethesda, Md; and GENFIT.SA (R.G., S.H.), Loos, France.

* To whom correspondence should be addressed. E-mail: helene.duez{at}pasteur-lille.fr.

Objective--The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I.

Methods and Results--In a head-to-head double-blind clinical trial, both FF and GF decreased triglycerides and increased HDL cholesterol levels to a similar extent, whereas plasma apoA-I only increased after FF but not GF. Results in human (h) apoA-Itransgenic (hA-ITg) peroxisome proliferator-activated receptor (PPAR) {alpha}-/- mice demonstrated that PPAR{alpha} mediates the effects of FF and GF on HDL in vivo. Although plasma and hepatic mRNA levels of hapoA-I increased more pronouncedly after FF than did GF in hA-ITgPPAR{alpha}+/+ mice, both fibrates induced acylCoAoxidase mRNA similarly. FF and GF transactivated PPAR{alpha} with similar activity and affinity on a DR-1 PPAR response element, but maximal activation on the hapoA-I DR-2 PPAR response element was significantly lower for GF than for FF. Moreover, GF induced recruitment of the coactivator DRIP205 on the DR-2 site less efficiently than did FF.

Conclusion--Both GF and FF exert their effects on HDL through PPAR{alpha}. Whereas FF behaves as a full agonist, GF appears to act as a partial agonist due to a differential recruitment of coactivators to the promoter. These observations provide an explanation for the differences in the activity of these fibrates on apoA-I.


Key words: apolipoprotein A-I • high-density lipoprotein • fibrates • peroxisome proliferator-activated receptor {alpha} • selective PPAR modulator




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
C. C. van der Hoogt, W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. G. Princen, J. W. Jukema, L. M. Havekes, and P. C. N. Rensen
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
J. Lipid Res., August 1, 2007; 48(8): 1763 - 1771.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. D. Brown and J. Plutzky
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Circulation, January 30, 2007; 115(4): 518 - 533.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. P. Vanden Heuvel, J. T. Thompson, S. R. Frame, and P. J. Gillies
Differential Activation of Nuclear Receptors by Perfluorinated Fatty Acid Analogs and Natural Fatty Acids: A Comparison of Human, Mouse, and Rat Peroxisome Proliferator-Activated Receptor-{alpha}, -{beta}, and -{gamma}, Liver X Receptor-{beta}, and Retinoid X Receptor-{alpha}
Toxicol. Sci., August 1, 2006; 92(2): 476 - 489.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Okopien, R. Krysiak, and Z. S. Herman
Effects of Short-Term Fenofibrate Treatment on Circulating Markers of Inflammation and Hemostasis in Patients with Impaired Glucose Tolerance
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1770 - 1778.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Ji, G. F. Watts, A. G. Johnson, D. C. Chan, E. M. M. Ooi, K.-A. Rye, A. P. Serone, and P. H. R. Barrett
High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 973 - 979.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Lan and D. L. Silver
Fenofibrate Induces a Novel Degradation Pathway for Scavenger Receptor B-I Independent of PDZK1
J. Biol. Chem., June 17, 2005; 280(24): 23390 - 23396.
[Abstract] [Full Text] [PDF]